KNSA — Kiniksa Pharmaceuticals International Income Statement
0.000.00%
Last trade - 00:00- $3.74bn
- $3.32bn
- $677.56m
Annual income statement for Kiniksa Pharmaceuticals International, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 38.5 | 220 | 270 | 423 | 678 |
| Cost of Revenue | |||||
| Gross Profit | 29.4 | 197 | 237 | 362 | 600 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 195 | 210 | 295 | 469 | 600 |
| Operating Profit | -157 | 9.77 | -25.2 | -45.6 | 77.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -157 | 11 | -16.7 | -36.2 | 88.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -158 | 183 | 14.1 | -43.2 | 59 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -158 | 183 | 14.1 | -43.2 | 59 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -158 | 183 | 14.1 | -43.2 | 59 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.3 | 2.6 | 0.196 | -0.605 | 0.747 |